NVS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

13.70B

+4.17%

1.926

-2.73%

13.60B

+2.77%

1.950

-14.47%

13.60B

-3.23%

2.100

-13.22%

Estimates Revision

The market is revising No Change the revenue expectations for Novartis AG (NVS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 10.09%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.32%

In Past 3 Month

Stock Price

Go Up

+10.09%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast NVS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVS is 129.00 USD with a low forecast of 118.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

1 Sell

Moderate Sell

Current: 135.170

Low

118.00

Averages

129.00

High

140.00

Current: 135.170

Low

118.00

Averages

129.00

High

140.00

HSBC

Reduce

maintain

$106 -> $112

2025-12-10

Reason

HSBC

Price Target

$106 -> $112

2025-12-10

maintain

Reduce

Reason

HSBC raised the firm's price target on Novartis to $112 from $106 and keeps a Reduce rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."

JPMorgan

Neutral -> Overweight

upgrade

2025-12-08

Reason

JPMorgan

Price Target

2025-12-08

upgrade

Neutral -> Overweight

Reason

JPMorgan upgraded Novartis to Overweight from Neutral with a price target of CHF 125, up from CHF 95. The firm adjusted ratings in the European pharma group as part of its 2026 outlook. It expects sector performance to be driven by pipeline readouts, saying much of the concern around the impact of U.S. price pressure on sector earnings has dissipated in Q4. JPMorgan downgraded companies with a lack of pipeline readouts in 2026.

Morgan Stanley

Overweight

maintain

$136 -> $143

2025-12-03

Reason

Morgan Stanley

Price Target

$136 -> $143

2025-12-03

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Novartis to $143 from $136 and keeps an Overweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.

BofA

Neutral -> Buy

upgrade

2025-11-25

Reason

BofA

Price Target

2025-11-25

upgrade

Neutral -> Buy

Reason

BofA upgraded Novartis to Buy from Neutral with a price target of CHF 117, up from CHF 111. A long-standing overhang for investors has been the company's substantial patent cliffs into the end of the decade, with Cosentyx, Kesimpta and Kisqali, but the firm notes that the company already has several launches succeeding - including Pluvicto, Scemblix, and Leqvio - with new launches likely to add in Rhapsido and ianalumab.

Morgan Stanley

Equal Weight -> Overweight

upgrade

2025-10-31

Reason

Morgan Stanley

Price Target

2025-10-31

upgrade

Equal Weight -> Overweight

Reason

Morgan Stanley upgraded Novartis to Overweight from Equal Weight with a price target of CHF 110, up from CHF 108. The firm cites valuation for the upgrade following the recent shared selloff. Novartis is underdoing an improving portfolio mix into the upcoming Rhapsido launch, the analyst tells investors in a research note. Morgan Stanley expects the company's 2026 growth to be modest, but anticipates an acceleration from 2027.

Morgan Stanley

Equal Weight

maintain

2025-10-27

Reason

Morgan Stanley

Price Target

2025-10-27

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Novartis to CHF 108 from CHF 105 and keeps an Equal Weight rating on the shares.

Valuation Metrics

The current forward P/E ratio for Novartis AG (NVS.N) is 14.78, compared to its 5-year average forward P/E of 13.00. For a more detailed relative valuation and DCF analysis to assess Novartis AG 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

13.00

Current PE

14.78

Overvalued PE

16.26

Undervalued PE

9.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

11.54

Current EV/EBITDA

11.74

Overvalued EV/EBITDA

12.35

Undervalued EV/EBITDA

10.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.03

Current PS

4.66

Overvalued PS

4.39

Undervalued PS

3.66

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NVS News & Events

Events Timeline

No data

News

6.5

09:00 AMNASDAQ.COM

Zacks Analyst Insights: Microsoft, Novartis, RTX, and Air T

6.5

12-15NASDAQ.COM

Key Research Updates on Microsoft, Novartis, and RTX

7.5

12-12Globenewswire

Novartis Breaks Ground on 700,000-Square-Foot Manufacturing Hub in North Carolina

People Also Watch

Frequently Asked Questions

What is Novartis AG (NVS) stock price today?

The current price of NVS is 135.17 USD — it has decreased -0.01 % in the last trading day.

What is Novartis AG (NVS)'s business?

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

What is the price predicton of NVS Stock?

What is Novartis AG (NVS)'s revenue for the last quarter?

Novartis AG revenue for the last quarter amounts to 14.36B USD, increased 9.00 % YoY.

What is Novartis AG (NVS)'s earnings per share (EPS) for the last quarter?

Novartis AG. EPS for the last quarter amounts to 2.02 USD, increased 28.66 % YoY.

What changes have occurred in the market's expectations for Novartis AG (NVS)'s fundamentals?

How many employees does Novartis AG (NVS). have?

Novartis AG (NVS) has 75883 emplpoyees as of December 16 2025.

What is Novartis AG (NVS) market cap?

Today NVS has the market capitalization of 259.36B USD.